Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

Vascular cognitive impairment and dementia (VCID) encompasses a heterogeneous group of disorders in which cerebrovascular pathology contributes to cognitive decline. Accumulating evidence from both clinical and basic studies suggests that neuroinflammation is one of the major mechanisms underlying VCID pathogenesis. However, its clinical evaluation remains challenging, and how it influences the process of VCID pathogenesis is still not fully understood. Experimental models of chronic cerebral hypoperfusion have demonstrated that decreased cerebral blood flow can activate innate immune responses and trigger inflammatory cascades. These cascades may contribute to white matter damage and cognitive deficits, and anti-inflammatory interventions have shown therapeutic potential in mitigating these outcomes. In this mini-review, we summarize recent findings on neuroinflammation from both clinical and basic studies, and discuss its role in VCID progression. A deeper understanding of the multifaceted mechanisms involved in inflammatory signaling will be essential for advancing VCID research and developing effective therapeutic strategies.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mizutani, A., Parra-Pérez, C., Shindo, A., Lizasoaín, I., Moro, M. Á., & Arai, K. (2026). Neuroinflammation in vascular cognitive impairment and dementia: Insights from clinical biomarkers and experimental models. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1177/0271678x261437523

Vancouver

Mizutani A, Parra-Pérez C, Shindo A, Lizasoaín I, Moro MÁ, Arai K. Neuroinflammation in vascular cognitive impairment and dementia: Insights from clinical biomarkers and experimental models. Journal of Cerebral Blood Flow & Metabolism. 2026. doi:10.1177/0271678x261437523. PMID: 41964274.

BibTeX

@article{mizutani2026-41964274,
  author  = {Mizutani, Akane and Parra-Pérez, Carlos and Shindo, Akihiro and Lizasoaín, Ignacio and Moro, María Ángeles and Arai, Ken},
  title   = {{Neuroinflammation in vascular cognitive impairment and dementia: Insights from clinical biomarkers and experimental models}},
  journal = {Journal of Cerebral Blood Flow \& Metabolism},
  year    = {2026},
  doi     = {10.1177/0271678x261437523},
  pmid    = {41964274},
  url     = {https://doi.org/10.1177/0271678x261437523}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review summarizes evidence that neuroinflammation is a major mechanism in vascular cognitive impairment and dementia, and that anti-inflammatory interventions have shown therapeutic potential in experimental models. As a review of clinical and basic studies, it does not itself demonstrate a treatment, cure or prevention.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Cerebral Blood Flow & Metabolism)
Journal's citation record 3 / 4 Journal of Cerebral Blood Flow & Metabolism: journal h-index 285 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 2 / 6 Cited 2.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Ken Arai: h-index 69 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 5 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41964274)
Free to read 2 / 2 Free to read
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Related studies in Inflammation and the immune system

Also tagged “vessel”

900 studies in the library carry the topic tag “vessel”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →